



Report Number: 20-005907/D01.R00

Report Date: 06/15/2020 ORELAP#: OR100028

Purchase Order:

Received: 06/09/20 14:00

Customer: Nightingale Remedies Product identity: #1 CBD Tincture

Client/Metrc ID:

Laboratory ID: 20-005907-0001 Sample Date: 06/09/20

Summary

| Analyte per 1oz. CBD per 1oz. CBDV per 1oz. CBDV per 1oz. Result Limits Units Status Mg/1oz. Mg/1oz. THC-Total per 1oz. CLOQ | Potency: | | | | | | |
|--|------------------|--------|--------|---------|--------|--------------------|-------------|
| | Analyte per 1oz. | Result | Limits | Units | Status | CBD-Total per 1oz. | 757 mg/1oz. |
| THC-Total per Toz. | · | _ | | Ü | | THC Total par 107 | <100 |
| (Reported in milligrams per serving) | 000 (poi 102. | 0.00 | | g, 102. | | - | |





Report Number: 20-005907/D01.R00

Report Date: 06/15/2020 ORELAP#: OR100028

Purchase Order:

06/09/20 14:00 Received:

Customer: Nightingale Remedies

Product identity: #1 CBD Tincture

Client/Metrc ID:

Sample Date: 06/09/20

20-005907-0001 Laboratory ID:

Relinquished by: Client Temp: 12.4 °C

Sample Results

| Potency per 1oz. | Method J AOA | C 2015 V98-6 (mod) | Batch: 2004897 | | Analyze: 6/11/20 3:11:00 PM |
|--------------------------|--------------|--------------------|----------------|-------|-----------------------------|
| Analyte | Result | Limits | Units | LOQ | Notes |
| CBC per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| CBC-A per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| CBC-Total per 1oz. | < LOQ | | mg/1oz. | 1.67 | |
| CBD per 1oz. | 757 | | mg/1oz. | 8.92 | |
| CBD-A per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| CBD-Total per 1oz. | 757 | | mg/1oz. | 9.70 | |
| CBDV per 1oz. | 3.83 | | mg/1oz. | 0.892 | |
| CBDV-A per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| CBDV-Total per 1oz. | 3.83 | | mg/1oz. | 1.66 | |
| CBG per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| CBG-A per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| CBG-Total per 1oz. | < LOQ | | mg/1oz. | 1.66 | |
| CBL per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| CBN per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| $\Delta 8$ -THC per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| Δ 9-THC per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| THC-A per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| THC-Total per 1oz. | < LOQ | | mg/1oz. | 1.67 | |
| THCV per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| THCV-A per 1oz. | < LOQ | | mg/1oz. | 0.892 | |
| THCV-Total per 1oz. | < LOQ | | mg/1oz. | 1.67 | |
| Total Cannabinoids 1oz. | 761 | | mg/1oz. | | |





Report Number: 20-005907/D01.R00

Report Date: 06/15/2020 ORELAP#: OR100028

Purchase Order:

06/09/20 14:00 Received:

These test results are representative of the individual sample selected and submitted by the client.

Abbreviations

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220

Limit(s) of Quantitation (LOQ): The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified degree of confidence.

† = Analyte not NELAP accredited.

Units of Measure

g = Grammg/1oz. = Milligram per 1oz. % = Percentage of sample

% wt = μ g/g divided by 10,000

Approved Signatory

Derrick Tanner General Manager





Report Number: 20-005907/D01.R00

Report Date: 06/15/2020

ORELAP#: OR100028

Purchase Order:

Received: 06/09/20 14:00

We have an account with you.

A Tentamus Company Nightingale Remedies



np Products **Custody Record**

F002 Rev: 02/27/2020 Eff: 02/27/2020

AP ID: **OR100028**

| Company: Street: Sept Round State: Officer Partial State: Officer Philosophic State: Officer Philosoph | 7 AVI 9721 | edie | S Non | A | nalysis F | Reque | ested | | | | Proje Pro Custon Report Tur | ect Number: oject Name: n Reporting: to State - □ M | ETRC or □ Oth : □ Standard □ *Ask for avail | er: Rush * Priority Rush * ability |
|--|---------------|------|-------|-------------|-----------|-------|-------|---|-----|-----------|--|---|---|--|
| Lab ID Client Sample Identification | Date | 6 | 101 | | | | | | | | Sample Type † | Report units (potency) | Serving size (edibles) | Comments/Metrc ID |
| #2 CBD Tincture #2 CBD Tincture Relinquished By: Da | b () | | | teceived by | | | Dat | | Tin | | | | Lab Use O | n luc |
| | 9 14200 | На | gi | 7 F | Hon | | o6/o | 9 | 14: | <u>C0</u> | □ Shippe Evidenc Sample i □ Cash Prelog st | ed Via: e of cooling: □ n good conditi □ Check □ C orage: | yes | or ☐ Client drop off emp (°C): |

† - Sample type codes:

Report unit options: %; mg/g; mg/serving

Samples submitted to CL with testing requirements constitute an agreement for services in accordance with the current terms of service associated with this COC. By signing "Relinquished by" you are agreeing to these terms.

Page 1 of 2

info@columbialaboratories.com

www.columbialaboratories.com

www.columbialaboratories.com

12423 NE Whitaker Way Portland, OR 97230

info@columbialaboratories.com





Report Number: 20-005907/D01.R00

Report Date: 06/15/2020

ORELAP#: OR100028

Purchase Order:

Received: 06/09/20 14:00



Hemp Products Chain of Custody Record

Revision: 0.00 Control#: CF002 Rev: 02/27/2020 Eff: 02/27/2020 ORELAP ID: OR100028

PRICING AND CHARGES

Prices to be charged for work performed for CUSTOMER are those currently published in the Columbia Laboratories (herein referred to as "the LAB". Standard pricing applies unless otherwise agreed in writing by the CUSTOMER and the LAB. CUSTOMER must notify the LAB of price quotation at the time of the transfer of sample(s) to the LAB. Any cancellation of testing requirements will result in charges being assessed on all testing completed prior to the notice of cancellation. Unless otherwise agreed upon, samples containing hazardous material will be shipped back to client at their expense, or disposed of at a certain fee, waste category dependent. New accounts are accepted with full payment in advance by cash, check, Visa or Mastercard. A credit line may be established with an approved credit application.

DELIVERY AND LIABILITY LIMITATIONS

The specific format of the goods will be defined by CUSTOMER to the LAB upon delivery of the sample(s) to the LAB. The LAB will analyze samples provided by CUSTOMER as requested by CUSTOMER in accordance with the procedures documented in the Quality Assurance Plan (QAP). Samples are retained for 30 days after receipt. If additional time is desired, then a written request is required, and an additional monthly fee will apply.

CONFIDENTIALITY

The LAB will treat all information regarding work performed for CUSTOMER as proprietary and confidential. No CUSTOMER information will be released to third persons without the written request of the CUSTOMER.

LIMITATION OF LIABILITY AND WARRANTY

The LAB gives no warranty, express or implied, or of fitness for a particular purpose, in connection with its analytical testing or reporting. Any liability of the LAB to CUSTOMER or any third party shall be limited to the cost of analysis charged to CUSTOMER.

PAST DUE ACCOUNTS

Credit line account are payable within 30 days. Accounts that are 60 days past due will incur 11/2% per month on all past due sums until paid in full and will automatically default to cash on delivery (COD). Reports will not be released unless payment on past and current invoices are received. Customer agrees to pay the interest as a service charge and all the LAB's collection costs, including reasonable attorney fees.

EXPERT TESTIMONY AND COURT APPEARANCES

In the event CUSTOMER requires the further written opinion or testimony of any employee of the LAB, including response to a subpoena issued by CUSTOMER or any third person, CUSTOMER agrees to pay such additional fees and expenses as may be reasonably assessed by the LAB.

ALTERNATIVE DISPUTE RESOLUTION (ADR)

Any disputes arising out of this Agreement or the analytical testing or reporting by the LAB shall be settled through mediation and/or arbitration rather than litigation, and the cost of the ADR shall be borne equally by both parties.

APPLICABLE LAW

Legal matters arising from work performed by the LAB for CUSTOMER will be construed and interpreted in accordance with the laws for the state of Oregon. When sending, transferring, or submitting samples, the CUSTOMER assumes full responsibility for complying with all applicable state and federal laws

Samples submitted to CL with testing requirements constitute an agreement for services in accordance with the current terms of service associated with this COC. By signing "Relinquished by" you are agreeing to these terms.

2 (623) 254-1452 Page 7 of 7

12423 NE Whitaker Way Portland, OR 97230

info@columbialaboratories.com

www.columbialaboratories.com





20-005907/D01.R00 **Report Number:**

Report Date: 06/15/2020 ORELAP#: OR100028

Purchase Order:

Received: 06/09/20 14:00

Revision #: 0.00 Control : CFL-D06 Revision Date: 05/31/2019 Effective Date: 05/31/2019

Laboratory Quality Control Results

| J AOAC 2015 | V98-6 | | ato. y | | | | |
|---------------|---------------|-------|--------|-------|------------|------------|-------|
| Laboratory Co | ontrol Sample | | | | | | |
| Analyte | Result | Spike | Units | % Rec | Limits | Evaluation | Notes |
| CBDV-A | 0.0103 | 0.01 | % | 103 | 85.0 - 115 | Acceptable | |
| CBDV | 0.0102 | 0.01 | % | 102 | 85.0 - 115 | Acceptable | |
| CBD-A | 0.00945 | 0.01 | % | 94.5 | 85.0 - 115 | Acceptable | |
| CBG-A | 0.0101 | 0.01 | % | 101 | 85.0 - 115 | Acceptable | |
| CBG | 0.00987 | 0.01 | % | 98.7 | 85.0 - 115 | Acceptable | |
| CBD | 0.00897 | 0.01 | % | 89.7 | 85.0 - 115 | Acceptable | |
| THCV | 0.00981 | 0.01 | % | 98.1 | 85.0 - 115 | Acceptable | |
| THCVA | 0.0100 | 0.01 | % | 100 | 85.0 - 115 | Acceptable | |
| CBN | 0.00984 | 0.01 | % | 98.4 | 85.0 - 115 | Acceptable | |
| THC | 0.0103 | 0.01 | % | 103 | 85.0 - 115 | Acceptable | |
| D8THC | 0.00991 | 0.01 | % | 99.1 | 85.0 - 115 | Acceptable | |
| CBL | 0.0101 | 0.01 | % | 101 | 85.0 - 115 | Acceptable | |
| CBC | 0.0104 | 0.01 | % | 104 | 85.0 - 115 | Acceptable | |
| THCA | 0.00894 | 0.01 | % | 89.4 | 85.0 - 115 | Acceptable | |
| CBCA | 0.00993 | 0.01 | % | 99.3 | 85.0 - 115 | Acceptable | |

Method Blank

| Analyte | Result | 1 | LOQ | Units | Limits | Evaluation | Notes |
|---------|---|---|-------|-------|---------|------------|-------|
| CBDV-A | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| CBDV | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| CBD-A | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| CBG-A | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| CBG | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| CBD | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| THCV | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| THCVA | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| CBN | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| THC | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| D8THC | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| CBL | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |
| CBC | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td>·</td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | · |
| THCA | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td>·</td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | · |
| CBCA | <loq< td=""><td>C</td><td>0.003</td><td>%</td><td>< 0.003</td><td>Acceptable</td><td></td></loq<> | C | 0.003 | % | < 0.003 | Acceptable | |

Abbreviations

ND - None Detected at or above MRL RPD - Relative Percent Difference LOQ - Limit of Quantitation

Units of Measure:

% - Percent





Report Number: 20-005907/D01.R00

Report Date: 06/15/2020 ORELAP#: OR100028

Purchase Order:

Received: 06/09/20 14:00

Revision #: 0.00 Control : CFL-D06 Revision Date: 05/31/2019 Effective Date: 05/31/2019

Laboratory Quality Control Results

| J AOAC 2015 | V98-6 | | | | Bate | h ID: 2004897 | 7 | | | |
|--------------|---|---|-------|-------|-------|---------------|------------|-------|--|--|
| Sample Dupli | icate | Sample ID: 20-005209-0004-01 | | | | | | | | |
| Analyte | Result | Org. Result | LOQ | Units | RPD | Limits | Evaluation | Notes | | |
| CBDV-A | <loq< td=""><td><loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.003 | % | NA | < 20 | Acceptable | | | |
| CBDV | 0.0353 | 0.0351 | 0.003 | % | 0.806 | < 20 | Acceptable | | | |
| CBD-A | <loq< td=""><td><loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.003 | % | NA | < 20 | Acceptable | | | |
| CBG-A | <loq< td=""><td><loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.003 | % | NA | < 20 | Acceptable | | | |
| CBG | 0.0688 | 0.0683 | 0.003 | % | 0.694 | < 20 | Acceptable | | | |
| CBD | 3.50 | 3.13 | 0.003 | % | 11 | < 20 | Acceptable | | | |
| THCV | 0.00575 | 0.00572 | 0.003 | % | 0.537 | < 20 | Acceptable | | | |
| THCVA | <loq< td=""><td><loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.003 | % | NA | < 20 | Acceptable | | | |
| CBN | 0.00315 | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.003 | % | NA | < 20 | Acceptable | | | |
| THC | <loq< td=""><td><loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.003 | % | NA | < 20 | Acceptable | | | |
| D8THC | <loq< td=""><td><loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.003 | % | NA | < 20 | Acceptable | | | |
| CBL | <loq< td=""><td><loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td>•</td></loq<></td></loq<> | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td>•</td></loq<> | 0.003 | % | NA | < 20 | Acceptable | • | | |
| CBC | <loq< td=""><td><loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td>•</td></loq<></td></loq<> | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td>•</td></loq<> | 0.003 | % | NA | < 20 | Acceptable | • | | |
| THCA | <loq< td=""><td><loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td>•</td></loq<></td></loq<> | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td>•</td></loq<> | 0.003 | % | NA | < 20 | Acceptable | • | | |
| CBCA | <loq< td=""><td><loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.003</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.003 | % | NA | < 20 | Acceptable | | | |

Abbreviations

ND - None Detected at or above MRL RPD - Relative Percent Difference LOQ - Limit of Quantitation

NA - Calculation Not Applicable given non-numerical results

Units of Measure:

% - Percent





20-005907/D01.R00 **Report Number:**

Report Date: 06/15/2020 ORELAP#: OR100028

Purchase Order:

Received: 06/09/20 14:00

Explanation of QC Flag Comments:

| Code | Explanation |
|------|---|
| Q | Matrix interferences affecting spike or surrogate recoveries. |
| Q1 | Quality control result biased high. Only non-detect samples reported. |
| Q2 | Quality control outside QC limits. Data considered estimate. |
| Q3 | Sample concentration greater than four times the amount spiked. |
| Q4 | Non-homogenous sample matrix, affecting RPD result and/or % recoveries. |
| Q5 | Spike results above calibration curve. |
| Q6 | Quality control outside QC limits. Data acceptable based on remaining QC. |
| R | Relative percent difference (RPD) outside control limit. |
| R1 | RPD non-calculable, as sample or duplicate results are less than five times the LOQ. |
| R2 | Sample replicates RPD non-calculable, as only one replicate is within the analytical range. |
| LOQ1 | Quantitation level raised due to low sample volume and/or dilution. |
| LOQ2 | Quantitaion level raised due to matrix interference. |
| В | Analyte detected in method blank, but not in associated samples. |
| B1 | The sample concentration is greater than 5 times the blank concentration. |
| B2 | The sample concentration is less than 5 times the blank concentration. |